After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with ...

Opus Genetics has completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug ...

An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered ...

An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and ...

An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored ...

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...

In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance ...

Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.

4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your ...